sur ABIVAX (EPA:ABVX)
Abivax Prepares for General Meeting with Document Release
On April 20, 2026, Abivax SA announced the upcoming Annual Ordinary and Extraordinary General Meeting scheduled for May 11, 2026. This event will take place at the Paris Marriott Opera Ambassador hotel in Paris. The biotechnology company, operating in the clinical-stage sector, focuses on developing treatments for chronic inflammatory diseases by leveraging the body's natural regulatory mechanisms.
Documents preparatory to the General Meeting, including the agenda and draft resolutions, are accessible to shareholders. These were initially published in the Bulletin des Annonces Légales Obligatoires on April 3, 2026. The information is also available on the company's official website in compliance with legal provisions.
Abivax's lead candidate, obefazimod, is presently advancing through Phase 3 clinical trials for ulcerative colitis, reflecting the company's ongoing commitment to innovative therapeutic solutions.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIVAX